RSVpreF Vaccine for RSV

This trial tests a vaccine called RSVpreF to evaluate its safety and effectiveness in individuals with weakened immune systems. The researchers aim to determine the optimal schedule for revaccination every 1, 2, or 3 years. Participants must be 18 or older, have a weakened immune system, and either have received the RSV vaccine before or be new to it. Each participant will receive one shot and visit the study site at least four times over a year. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study contact or your doctor.

Research has shown that the RSVpreF vaccine is generally safe and well-tolerated. In studies, most participants experienced only mild side effects, such as sore arms, headaches, muscle pain, and nausea. However, a small risk exists for a serious nerve condition called Guillain-Barré syndrome, which occurred in about 18 cases per million doses. While rare, this risk is important to note. Overall, the vaccine has demonstrated a good safety record across various studies.¹²³⁴⁵

Researchers are excited about the RSVpreF Vaccine because it targets respiratory syncytial virus (RSV) with a novel approach. Unlike current treatments that primarily manage symptoms, like bronchodilators and corticosteroids, this vaccine aims to prevent RSV by prompting the immune system to recognize and fight the virus before it causes illness. The RSVpreF Vaccine uses a stabilized prefusion form of the RSV F protein, which is a key structure the virus uses to enter cells, potentially offering stronger and more targeted immunity. This could mean fewer RSV infections and hospitalizations, especially in vulnerable populations like infants and the elderly.

Research has shown that the RSVpreF vaccine effectively prevents respiratory syncytial virus (RSV) infections, particularly in high-risk individuals. One study found the vaccine to be 90% effective in preventing severe RSV cases in older adults. Another study demonstrated an 83.3% effectiveness in reducing hospital visits due to RSV. Additionally, the vaccine triggered strong immune responses in adults with ongoing health issues. Overall, the evidence suggests that the RSVpreF vaccine offers a promising means of protection against severe RSV infections.⁶⁷⁸⁹¹⁰